

Effect of Tramadol Dependence on The Immune System In A Sample Of Egyptian Male Patients

Thesis

Submitted for partial fulfillment of M.D. degree in Psychiatry

By

Dr. Ehab Hassan Elbaz

M.B.B.Ch., M.Sc. of Neuropsychiatry

Supervised by

Prof. Mohamed Hamed Ghanem

Professor of Psychiatry

Faculty of Medicine - Ain Shams University

Prof. Amany Haroun EL-Rasheed

Professor of Psychiatry

Faculty of Medicine - Ain Shams University

Prof. Abeer Mahmoud Eissa

Professor of Psychiatry

Faculty of Medicine - Ain Shams University

Prof. Mohamed Reda Abd Elraoof

Professor of psychiatry

Military Medical Academy – Egyptian Armed Forces

Dr. Ahmed Nabeeh Agam

Head of the Laboratory Department

Maadi Armed Forces Hospital

Faculty of Medicine

Ain Shams University

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

First and foremost, thanks to ALLAH, the real support and the guidance which gave me the power to work.

I would like to thank cardinally and to express deepest sense of gratitude to **Prof. Mohamed Hamed Ghanem** Professor of Psychiatry, Faculty of Medicine, Ain Shams University for his valuable and fruitful guidance, continuous encouragement and keep supervision. He gave me much of his time and effort. Without his help this work would not be possible.

I wish to express my warm and sincere thanks gratefulness to **Prof. Amany Haroun EL-Rasheed** Professor of Psychiatry, Faculty of Medicine, Ain Shams University. She has generously devoted effort to supervise the work. I am especially thankful for her valuable advice and meticulous guidance throughout the course of this work.

I would like to express my cordial appreciation and gratefulness to **Prof. Abeer Mahmoud Eissa**, Professor of Psychiatry, Faculty of Medicine, Ain Shams University for her effort and limitless support.

Thanks to **Prof. Mohamed Reda Abd Elraoof**, Professor of Psychiatry, Military Medical Academy for his ultimate support and encouragement through the whole work and before.

Many thanks to **Dr. Ahmed Nabeeh Agam**, Head of the Laboratory Department, Maadi Armed Forces Hospital and our colleagues in the laboratory departments in the Armed Forces Medical Services for their generous help and support in completing this work.

I would like to express my sincere gratitude to **Major General Dr. Ahmed Eltawdy**, Head of the Military Medical Academy for the real support that can be touched

I wish to express my sincere gratitude to the cooperative patients who agreed to participate in this research.

No words can express my genuine gratitude, deep appreciation and great love to my wife and my children for their patience, encouragement and support.

Dr. Dr. Ehab Hassan Elbaz



List of Contents

<i>Title</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	ii
List of Figures.....	iv
Introduction	1
Aim of the Work.....	6
<u>Review of literature</u>	
Chapter (1): Epidemiology of tramadol dependence.....	7
Chapter (2): Pharmacology of tramadol	34
Chapter (3): Pharmacology of naltrexone.....	60
Chapter (4): Opiates and the immune system.....	89
Subjects and methods	113
Results	125
Discussion.....	147
Conclusion	164
Limitations	165
Recommendations	166
Summary	168
Reference	176
Appendices	204
Arabic summary	--

List of Abbreviations

<i>Abbr.</i>	<i>Full term</i>
ACMD	Advisory Council on Misuse of Drugs
AIS	adaptive immune system
AUC	area under the concentration-time curve
BMI	body mass index
CNS	central nervous system
GLC	gas-liquid chromatography
GPCR	G-protein coupled receptor
HPLC	high-performance liquid chromatography
IFN	Interferon
IIS	innate immune system
IL	Interleukin
IR	Immediate-release
MBL	mannose-binding protein
MHC	major histocompatibility complex
MMT	methadone maintenance treatment
MOR	μ opioid receptor
MS	multiple sclerosis
NK	natural killer cells
NO	nitric oxide
NRAP	National Research Addiction Program
PAMP	pathogen-associated molecular pattern
PRR	pattern recognition receptor
REMS	Risk Evaluation and Mitigation Strategy
SR	sustained-release
Th	T-helper
TIR	Toll/interleukin-1 receptor
TLC	thin-layer chromatography
TLR	Toll-like receptor

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	The prevalence of illicit drug use in Egypt in 2009 according to the National Research of Addiction program	13
Table (2):	Type of substances used in the Egyptian regions.....	21
Table (3):	A study done by Abo-Elmagd et al. (2013) about tramadol use in 3 non-governmental hospitals and one private hospital in Cairo	27
Table (4):	Opiate detoxification.....	77
Table (5):	Specific drugs and laboratory tests	86
Table (6):	Opioid effects on immunity	103
Table (7):	Degree of immune modulation with different opioids in animal studies.....	106
Table (8):	Sociodemographic and clinical characteristics of the studied patients.....	125
Table (9):	Results of SCID-II of the studied patients	126
Table (10):	Results of the addiction severity index of the studied patients.....	127
Table (11):	Immunological parameters of the studied patients at baseline.....	128
Table (12):	Comparison between naltrexone-prescribed group and naltrexone-free group according to baseline Sociodemographic and clinical characteristics	129
Table (13):	Comparison between naltrexone-free and naltrexone-prescribed group according to SCID-II.....	130
Table (14):	Comparison between naltrexone-free and naltrexone-prescribed group according to ASI severity profile	131

List of Tables

Table (15):	Comparison between naltrexone-free and naltrexone-prescribed group regarding the immunological parameters at baseline	133
Table (16):	Comparison between naltrexone-free and naltrexone-prescribed group regarding the immunological parameters after 3 months	135
Table (17):	Comparison between naltrexone-free and naltrexone-prescribed group regarding the immunological parameters after 6 months	137
Table (18):	The difference in the level of IgG over the 6 months period in the naltrexone-free, naltrexone-prescribed group and total patients	139
Table (19):	The difference in the level of IgM over the 6 months period in the naltrexone-free, naltrexone-prescribed group.	140
Table (20):	The difference in the level of IgA over the 6 months period in the naltrexone-free, naltrexone-prescribed group	141
Table (21):	The difference in the level of IL-2 over the 6 months period in the naltrexone-free, naltrexone-prescribed group	142
Table (22):	The difference in the level of IL-6 over the 6 months period in the naltrexone-free, naltrexone-prescribed group	144
Table (23):	Correlation between immunological parameters after 6 months with age, duration of intake and age of onset, using Pearson Correlation Coefficient	145
Table (24):	Correlation between immunological parameters after 6 months with ASI severity profile, using Pearson Correlation Coefficient	146

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Chemical structure of tramadol	35
Figure (2):	Naltrexone hydrochloride.....	61
Figure (3):	Immune-regulation.....	95
Figure (4):	Bar chart between naltrexone-free and naltrexone-prescribed group according to ASI severity profile	132
Figure (5):	Bar chart between naltrexone-free and naltrexone-prescribed group according to IgA after 3 months.....	136
Figure (6):	Bar chart between naltrexone-free and naltrexone-prescribed group according to IgA after 6 months.....	138
Figure (7):	Line shows the difference in the level of IgG over the 6 months period in the naltrexone-free, naltrexone-prescribed group and total patients.....	139
Figure (8):	Line shows the difference over the periods through IgM in the naltrexone-free, naltrexone-prescribed group and total patients	141
Figure (9):	Line shows the difference over the periods through IgA in the naltrexone-free, naltrexone-prescribed group and total patients	142
Figure (10):	Line shows the difference over the periods through IL-2 in the naltrexone-free, naltrexone-prescribed group and total patients	143
Figure (11):	Line shows the difference over the periods through IL-6 in the naltrexone-free, naltrexone-prescribed group and total patients	144

INTRODUCTION

The nonmedical use of prescription opioid analgesics is an ongoing challenge. Its overall burden to society has been difficult to quantify, though it manifests itself in several ways, including the physical and psychological consequences of addiction and the effect of illicit use on physicians' prescribing habits. The financial burden associated with such misuse and abuse is significant, especially when such factors as associated health care and workplace costs and the cost of treatment for patients with opioid addiction are considered. (*Aaron and Paul, 2009*)

In USA, for example, the increase in abuse of marketed medications in recent years has highlighted the need for abuse-liability assessment. The numbers of new nonmedical users of four major classes of prescription-type drugs (pain relievers, tranquilizers, stimulants, and sedatives) increased between 1991 and 2001, with the largest increase in pain relievers. The number of primary treatment admissions for narcotic-analgesic abuse increased 76 percent between 1997 and 2000. (*Zacny et al., 2003*)

Tramadol [(±)-Trans-2-(dimethylaminomethyl)-1-(m-methoxyphenyl)-cyclohexanol hydrochloride] was introduced as a non-scheduled drug on the market in the UK in 1994 and in the USA in 1995 for treatment of moderate to moderately severe pain. It was first synthesized in 1962 and has been available in Germany since 1977. As a centrally acting analgesic, tramadol is atypical because it produces analgesia through both mu opioid and monoamine actions. The pharmacology of tramadol is further complicated by the fact that it is administered as a racemic mixture with two active enantiomers, each of which is biotransformed to an active metabolite: (+)-O-desmethyltramadol or (–)-O-desmethyltramadol. These metabolites are believed to be responsible for most of tramadol's mu-agonist properties. Clinically, the recommended dose of tramadol for mild to moderate pain is 50–100 mg every 6 hours p.o. or parenterally. Based on analgesic studies, tramadol is thought to be approximately one-tenth as potent as morphine when each is administered parenterally and approximately one-third as potent when each is administered orally. Tramadol has a low incidence of adverse effects, particularly of

respiratory depression, constipation and abuse potential.
(*David et al., 2006*)

An increasingly alarming phenomenon of Tramadol (Tramal, Amadol, Tramax, Contramal, Trama SR, Ultradol, Tramundin) abuse has been heavily demonstrated in the Egyptian community in the last four years. Though the issue of drug abuse is not new to Egyptian society, tramadol is associated with a wide range of abuse and illegal transactions that made it easily accessible and readily provided at cheap cost despite of it being scheduled. The alleged usages of tramadol contributed greatly to its popularity and massive use especially among youth and middle- aged groups as a remedy for premature ejaculation and for extended orgasm and to increase sexual pleasure as promoted in many online drug stores and media. (*Fawzi, 2011*)

The idea that opioids suppress the immune system and lower resistance to infections is not new. There is evidence that opioids modulate both innate and acquired immune responses, altering resistance to a variety of infectious agents. Acute and chronic administration of opioids is known to have inhibitory effect on humoral and cellular immune responses

including antibody production, natural killer lymphocyte activity, cytokine expression and phagocytic activity. Not all opioids induce the same degree of immunomodulatory effects. From reviewing the literature, it is evident that the majority of studies investigating the effects of opioids on the immune system have been conducted in animals. From these animal studies conclusions have been drawn that opioids can be divided into those that are immunosuppressive, such as codeine, methadone, morphine and remifentanyl. And those that are less immunosuppressive, including buprenorphine, hydromorphone, oxycodone and tramadol. (*Paola Sacerdote, 2006*)

Rationale of the study:

An increasingly alarming phenomenon of tramadol drug abuse has been demonstrated in the Egyptian community in the last few years (Fawzi, 2011). Few studies had examined the effect of tramadol abuse on the immune system and to our knowledge no Egyptian studies are conducted in this field , and whether the treatment from tramadol dependence restore the normal function of the immune system or not is not well understood .

Hypothesis:

The study hypotheses are:

1. Immune function is suppressed in Tramadol dependent male patients as compared to healthy controls.
2. Immune function will improve after 6 months of abstinence in Tramadol dependent patients.
3. Immune function will improve more in patients on naltrexone as compared to those not receiving naltrexone.

AIM OF THE WORK

- 1- To determine the effect of tramadol dependence on the immune system function.
- 2- To determine the effect of abstinence from tramadol dependence on the immune system.
- 3- To determine the effect of the opioid antagonist naltrexone on the immune system

Chapter (1)

Epidemiology of Tramadol Dependence

Epidemiological data:

Half of the US population aged twelve and above were current alcohol users (58.1 % were males). 22.7% had binge drinking (defined as five or more drinks on one occasion) at least once in the previous month, and 6.6 % reported being heavy drinkers. Illicit drug use was observed in (8.1%) of the total population above twelve years of age, the majority (54.5%) of whom used marijuana only, in the past month. Use of cocaine (1%), crack (0.3%), hallucinogens (0.4%) and heroin (0.1) were relatively lower) (*Luttermann et al., 2006*).

When compared to other regions, Europe had the highest alcohol consumption in the world. In 38 countries, the average alcohol consumption per person in 1998 was 7.3 liters; ranging from 0.9 liters (Azerbaijan) to 1303 liters per person (Luxembourg) (*Woelfer et al., 2001*).

The European National population surveys have shown that cannabis is the most commonly used substance in the European adult population (aged 15-64 years) ranging